TABLE 2.
Scedosporium infection: clinical response and site of infection
| Site(s) of infection, no. (%) | Range of therapy in days (median) | No. with successful outcome/total no. (%) | Known survival range in days (median) | No. of patients alive/total no. (no. of deaths due to scedosporiosis) |
|---|---|---|---|---|
| CNS, 21 (20) | 4-600 (115) | 9/21 (43) | 8->2,000 (116) | 10/21 (8) |
| Disseminated, 23 (21) | 1-691 (108) | 11/23 (48) | 2-816 (108) | 10/23 (12) |
| Bone, 19 (18) | 15-322 (140) | 15/19 (79) | 20-1,440 (147) | 18/19 (1) |
| Lung, sinus,a 26 (24) | 1-802 (101) | 14/26 (54) | 1-802 (101) | 14/26 (9) |
| Other body sites,b 7 (7) | 3-274 (42) | 2/7 (29) | 3-1,800 (275) | 5/7 (2) |
| Skin/subcutaneous, 11 (10) | 13-463 (100) | 10/11 (91) | 13-720 (178) | 8/11 (0) |
| Total, 107 | 1-802 (103) | 61/107 (57) | 1->2,000 (133) | 64/107 (32 IFIc) |
a
Lungs (25), sinus (one).
b
Other body sites: eye (three), ear (two), and vocal cord (one).
c
IFI, invasive fungal infection.